Found 218 articles
BeyondSpring Inc. announced that on January 4, 2024, it received a Foreign Delinquency Compliance Plan Alert Letter from The Nasdaq Stock Market LLC.
BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere Models
BeyondSpring Inc. announced that the Company and Professor Kathryn M. Eisenmann of the University of Toledo College of Medicine presented a poster on the potent efficacy of plinabulin in a derived patient model of glioblastoma, a disease of high unmet need at the 2023 AACR Special Conference in Cancer Research: Brain Cancer on Oct 20th, 2023 at Minneapolis, MN.
BeyondSpring Inc. announced that on October 27, 2023, it received a written notification from the Listing Qualifications Department from The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550 of the Nasdaq Listing Rules.
SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium
SEED Therapeutics Inc. announced at its Monday, October 23, 2023 Targeted Protein Degradation (TPD) Think Tank symposium that it had successfully discovered a ST-00937, a new chemical entity (NCE) molecular glue that has already achieved IND Candidate status and will be advanced for the treatment of cancers in SEED’s first IND filing, as early as 2024.
SEED Therapeutics has appointed eminent international lawyer Ko-Yung Tung to its Board of Directors.
BeyondSpring Inc. announced that on September 28, 2023, it received a written notification from The Nasdaq Stock Market LLC that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550, because the closing bid price of the Company’s ordinary shares was below $1.00 per share for 30 consecutive business days.
BeyondSpring Inc. announced the presentation of a poster at the Society for Immunotherapy of Cancer's 38th Annual Meeting, taking place on November 3 through 5 in San Diego, CA.
BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”) today announced that management will present and participate in the R.W. Baird’s 2023 Global Healthcare Conference, taking place on September 12 to 13, 2023 in New York City.
SEED Therapeutics, a BeyondSpring subsidiary and global research company focused on harnessing and engineering “molecular glues,” a targeted protein degradation platform to attack previously believed undruggable targets, announced that it has appointed Jackson Tai to its Board of Directors.
BeyondSpring and Leading Cancer Center Present Poster Highlighting Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCTData Presented at 2023 ASCO Annual Meeting
BeyondSpring Inc. today announced new data from a Phase 1 investigator initiated study highlighting a reduction in chemotherapy-induced infectious neutropenic fever with lead asset Plinabulin in combination with pegfilgrastim in multiple myeloma (MM) patients who underwent autologous hematopoietic stem cell transplantation (AHCT) and received a high dose of melphalan, a type of chemotherapy and one of the most active treatments for MM (NCT05130827).
BeyondSpring Inc. today announced that the Company and Memorial Sloan Kettering Cancer Center (MSK) will present a poster at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on June 2 through 6 in Chicago, IL.
BeyondSpring Inc. announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2022 with the U.S. Securities and Exchange Commission on April 18, 2023.
BeyondSpring Inc. provided a business update and reported results for the year ended December 31, 2022.
BeyondSpring Enrolls First Patient in Phase 2 Study with Plinabulin, Keytruda and Docetaxel in Patients with Metastatic Non-Small Cell Lung Cancer Who Progressed After Immunotherapy
BeyondSpring Inc. today announced that the first patient has been enrolled in BeyondSpring’s Phase 2 investigator-initiated trial with lead asset, Plinabulin, in combination with Merck’s anti-PD-1 therapy Keytruda® (pembrolizumab) and Docetaxel for previously treated patients with metastatic non-small cell lung cancer (NSCLC) and progressive disease after immunotherapy (anti-PD-1 / PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy.
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Patrick Fabbio as Chief Financial Officer effective January 30, 2023.
BeyondSpring Inc., a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies, announced that on December 29, 2022, the Company received a written notification from Nasdaq that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550.
BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conferences
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI) today announced data from the ESMO Asia Congress 2022 and the American Society of Hematology (ASH) Annual Meeting about the use of lead asset, plinabulin, for the prevention of docetaxel-induced neutropenia (DIN) in non-small cell lung cancer (NSCLC) patients.
BeyondSpring Inc. announced that on November 18, 2022, it received a written notification from The Nasdaq Stock Market LLC that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550, because the closing bid price of the Company’s ordinary shares was below $1.00 per share for 30 consecutive business days.
BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022
BeyondSpring Inc. announced data from a poster presentation at the ESMO Congress 2022 being held September 9-13, 2022, in Paris, France.
Elevar Therapeutics Names Dr. Jan M. Van Tornout Chief Medical Officer, Dr. Gordon Schooley Chief Regulatory Officer
Elevar Therapeutics, Inc., today announced the hiring of Jan M. Van Tornout, M.D., MSc., as chief medical officer, and Gordon Schooley, Ph.D., as chief regulatory officer.